PERCIST criteria to predict survival at 3 months following intra-arterial resin-based yttrium-90 (Y-90) radioembolization therapy of unresectable intrahepatic cholangiocarcinoma refractory to standard chemotherapy: A proof of concept study.
Juan C. Camacho
No relevant relationships to disclose
Nima Kokabi
No relevant relationships to disclose
David M. Schuster
No relevant relationships to disclose
Hyun Sik Kim
Consultant or Advisory Role - BTG (U)
Research Funding - Nordion; Novartis